VYR 206
Alternative Names: VYR-206Latest Information Update: 28 Sep 2024
At a glance
- Originator Vyripharm Biopharmaceutical
- Developer National Yang-Ming University; Vyripharm Biopharmaceutical
- Class Amides; Antihyperlipidaemics; Antineoplastics; Cannabinoids; Imaging agents; Obesity therapies; Piperidines; Pyrazoles; Small molecules; Smoking cessation therapies
- Mechanism of Action Bradykinin receptor antagonists; Cannabinoid receptor CB1 antagonists; Neurokinin 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diffuse large B cell lymphoma; Mantle-cell lymphoma; Neurological disorders
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Neurological-disorders(Diagnosis) in USA
- 28 Jul 2022 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in USA
- 28 Jul 2022 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma(Diagnosis) in USA